Für einen optimalen Ausdruck erlauben Sie bitte den Druck von Hintergrundfarben und -bildern

Press conference involving POSC and major company


Seite 1 von 3
Neuester Beitrag: 15.09.10 11:42
Eröffnet am: 23.04.10 20:21 von: 0815ax Anzahl Beiträge: 55
Neuester Beitrag: 15.09.10 11:42 von: 0815ax Leser gesamt: 13.019
Forum: Hot-Stocks   Leser heute: 4
Bewertet mit:
2


 
Seite: < 1 | 2 | 3 >  

4951 Postings, 4447 Tage 0815axPress conference involving POSC and major company

 
  
    #1
2
23.04.10 20:21

Press conference involving POSC and major  company may be announced as early as next Monday      
     
Written by Staff and Wire Reports   
Friday, 23 April 2010 05:48
 
biomedreports.com/articles/most-popular/37131-update-posc-rumors.html

Following up on the rumors we have been chasing  for two weeks, it appears that staffers at Positron Corporation  (OTCBB:POSC) have been busy making arrangements for a soon to be  announced press conference.

   This news according to multiple sources who also told BioMedReports on  Thursday that an official announcement about "a big development for the  company" may be issued as early as Monday.

Yesterday, prices took a hit after a blogger made false and  defamatory accusations against not only BioMedReports, but the company  as well. This is the second time that the blogger has attacked  BioMedReports's and owners of this website intend to take swift and  complete legal action against the owner/author of that web site. Thus  far, after multiple requests, the author of the website has refused to  provide us with his legal contact information so that our legal  department can commence those actions.

The fact remains that POSC is an established company that has been in  business for over a quarter of a century and that a positive  announcement- apparently worthy of a press conference- will be made  public in the coming days. Speculation continues that a multi-billion  dollar company trading on the NYSE at over $50 per share has taken an  interest in the company.

Furthermore, sources at the company tell BioMedReports that pending  orders for their FDA approved, Frost and Sullivan award winning imaging  system run at least "over one hundred deep."

As we told subscribers two days ago, we fully expect the stock price  to see substantial  gains (beyond the initial 43% gains seen immediately  after our trade alert) as it now appears that the company had  positioned itself to be the clear leader in  the five billion dollar  molecular imaging market. Positron's PET  (Positron Emission Tomography)  scanner, known as the “Attrius”, has  robust cardiac specific imaging  software and, more importantly, is the  only "PET" imaging device in the  entire industry (see related story).

In a letter to   shareholders last month, the chairman of the board for the company  informed investors that "Positron has  several immediate opportunities  with some of the largest companies in  the nuclear medicine industry.  Any combination of success with these  opportunities will have a  tremendous positive present and future impact  on Positron."

It is clear that a positive development worthy of a full press  conference (rumored arrangements place it at the Nasdaq MarketSite in  New York City) may be officially announced as early as Monday.

If true, naked shorters who took negative positions in the stock will  not only have to cover, they will help push the stock price much higher  by doing so.

Developing...

-----------
*amM - keine Kaufempfehlung

http://www.rot-weiss-erfurt.de/
29 Postings ausgeblendet.
Seite: < 1 | 2 | 3 >  

4951 Postings, 4447 Tage 0815axPositron Sells Its PET Scanner ...

 
  
    #31
06.05.10 08:13
May 5, 2010
http://www.nasdaq.com/aspx/...rdiac-diagnostic-services---quick-facts

Positron Sells Its PET Scanner To Manhattan Based Gramercy Cardiac Diagnostic Services - Quick Facts



(RTTNews) - Wednesday, Positron Corp. (POSC.OB) announced the sale and installation of its PET scanner to Manhattan based, Gramercy Cardiac Diagnostic Services, owned by prominent New York City cardiologist, Dr. Peter Rentrop.

Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution.

For comments and feedback: contact editorial@rttnews.com




Read more: http://www.nasdaq.com/aspx/...ic-services---quick-facts#ixzz0n7wjqvtW
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axPositron Showcased at NASDAQ Marketsite

 
  
    #32
06.05.10 22:13
http://www.finanznachrichten.de/...cased-at-nasdaq-marketsite-004.htm

06.05.2010 21:55
Positron Showcased at NASDAQ Marketsite

Positron Corporation (OTCBB:POSC) (the "Company") a molecular imaging solutions company focused on Nuclear Cardiology, announced the highlights from the Company's presentation before NASDAQ on May 5, 2010.

The Management of Positron Corporation introduced the Company at the NASDAQ Marketsite. This forum is of great value to Positron since it provides broad exposure and access to a far reaching investment community.

The Company set out to explain the foundation of its business, the confirmation of a strategic partnership and potential revenue. Management discussed most all aspects of the Company's plans which it was at liberty to disclose. A transcript of the presentation will be filed with the Securities and Exchange Commission on a Form 8-K immediately when it becomes available in coming days.

Positron representatives did confirm an agreement with an industry leading strategic partner that will give the Company the ability to greatly expand the Company's revenue stream and our position in the molecular imaging market by offering imaging systems and radiopharmaceutical distribution. Patrick Rooney, Positron Corporation's CEO states, "We would have liked to introduce a certain synergistic business partner as was stated in the press; however it was the recommendation of both companies to not disclose further details due to a potential expansion relationship and certain strategic competitive advantages. We anticipate additional information will be disclosed in the near future."

Positron also gave guidance as to its target revenue. Based on the Company's research and unique positioning in the marketplace, Positron projects significant sales growth quarter over quarter, year over year. Positron projects that in the next 5 years the nuclear cardiology market will approach $1.5 Billion in revenue annually. The projections reflected sales from Positron's PET device and radiopharmaceutical devices and services. Positron may potentially achieve greater revenue as it expands into new markets with broader indications that we expect will be fully supported by Medicare and private payers.

About Positron: Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at (317) 576-0183.

Contacts:

Positron Corporation
Patrick Rooney
(317) 576-0183



© 2010 Business Wire
-----------
*amM - keine Kaufempfehlung

730 Postings, 5073 Tage OttomanRosendahldas macht doch wieder Sinn, erklärt die

 
  
    #33
1
06.05.10 22:16
Haltung des Management am tag der Conference bezgl. Partnerschaftserklärung....


Sollte dem Aktienkurs wieder Schub geben ; )  

4951 Postings, 4447 Tage 0815axStock Alert for Positron Corp. - May 10th, 2010

 
  
    #34
1
10.05.10 18:43
http://www.microstockprofit.com/2010/05/10/...for-positron-corp-posc/
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815ax...multiple sources - Positron has partnered

 
  
    #35
1
15.05.10 19:24

POSC: Damned if you do and damned if you don't      
     
Written by Peter DePalma   
Friday, 14 May 2010 05:47
 
biomedreports.com/articles/most-popular/40359-posc-damned-if-you-do-and-damned-if-you-dont.html

After  alerting members to Positron Corporation (OTC:POSC), the stock roared  from $.06 to a fifty-two week high of $.30. Shortly after that, we advised our readers and subscribers that they  should consider selling their positions in POSC before the scheduled  press conference, fearing that the event could become a "buy on rumor  sell on news" event.

   

We've come back from vacation to an email box full of both love and  hate mail, thus the title of today's article.

Apparently, our advice to "sell" prior to the press event did not go  over well with many of the longs who felt that we were sending mixed  messages about the stock, but after carefully considering what many day  traders do with these "forward looking" types of stock plays, our  editors felt strongly that we should advise our readers despite the  potential for back lash.

As it turned out, things got even uglier than any of us expected when  the company decided not to announce their highly anticipated  partnership details to an audience of reporters in attendance at New  York's Nasdaq Marketsite. Most of the reporters covering the event  didn't even blink, but the tens of thousands of investors who were  following the conference via webcast immediately responded by dumping  their shares. What resulted was a wave of attacks and false accusations  about BMR promoting and/or pumping and dumping the stock. Those who  followed the advice and erred on the side of caution won while those who  decided to gamble more speculatively paid a price.

At the end of the day, the facts still remain: POSC is a solid  company that has been around for over 27 years. The CEO may need more  media relations training given his very rough delivery at the podium,  but  reporters at the event (none of whom even asked about the  partnership details that investors were craving) seemed to take the most  interest in management's announcement that POSC anticipates generating  over $200 million in revenue within 18 months and over a billion in  revenue within 4 to 5 years. This is a stock that many of us have jumped  back in on and is still available for mere pennies per share.

Even though they fully intended to when the news conference was  scheduled, POSC could not announce the name of the key partnership they  wanted to reveal at the press conference for a number of reasons. As we  understand it, there are at least one contractual and several strategic  partnerships in the works or even already in place. As many disappointed  and angry investors called and cried for full disclosure under threats  of lawsuits, the company followed up with a cryptic press release about  the matter in the days following the conference. Although no one at the  company can go on record publicly for the same reasons we mentioned, we  have confirmed to the best of our abilities and based on candid  interviews with multiple sources, that Positron has partnered with  Covidien (NYSE:COV). In addition, our sources tell us that they are also  in the process of aligning with other big board companies for some very  important strategic partnerships on the pharmaceutical side of the  business. Furthermore, it's worth considering that any one of these  strategic partners may choose to take a position in or even outright buy  the company; especially once the new network of automated imaging drug  dispensing machines is set up.

BMR was told that at one point, one of Positron's newest allies had  apparently gone so far as to "threaten them" before deciding that  joining  forces might be a better way to respond to their innovative  nuclear medicine's dispensing and distribution technology. The bonding  experience with that company is still shaky, but much more friendly now  according to those familiar with the situation and it definitely played  into why the company decided against the public revelations.

If  one looks at POSC and it's FDA approved PET Scan imaging technologies,  the back orders for systems, and the shift not only in the marketplace,  but also the reimbursement as well as medical and technical needs of the  cardio and oncology imaging space, it's clear to see that the company  is not only undervalued, but vastly undervalued. Look up IMGG and you'll  find a company that traded at close to $2 per share this year based on  only "half the promise" that POSC offers today. That company has  submitted for FDA approvals several times and still have no clearance,  yet they still trade today at nearly fifty cents per share.

Is  the company trading higher than it was when we first covered it?  Absolutely, and it is difficult to argue that the share price will not  continue to rise as future revenues, orders and developments are  announced. Do we continue to see it as a multi-bagger? Of course we do.  Especially given the fact that the entire space they deal in is changing  and that they are positioned without a single competitor as the leading  company within that space.

-----------
*amM - keine Kaufempfehlung

730 Postings, 5073 Tage OttomanRosendahlFalls Covidien der Partner sein sollte, was

 
  
    #36
1
15.05.10 19:54
bereits spekuliert wurde, dann sehen wir wirklich Kurse in $ bereichen.  

730 Postings, 5073 Tage OttomanRosendahlNEWS

 
  
    #37
1
21.05.10 17:53
Positron Sees Tenfold Increase in Attrius Quote  Proposals

 

Press Release   Source: Positron Corporation           On Friday May 21, 2010, 11:12 am
                           

INDIANAPOLIS--(BUSINESS WIRE)--Positron  Corporation (OTCBB:POSC)         (the “Company”) a molecular imaging solutions company focused on  Nuclear        Cardiology, states that over the first 4 months of 2010 that it  has seen        tremendous interest in its Attrius™ dedicated cardiac PET scanner.  The        Attrius™ was introduced in the 4th quarter of 2009 and  has        been met with critical acclaim throughout the molecular imaging  industry.

Patrick G. Rooney, Positron Corporation’s CEO states,  “The Nuclear        Cardiology industry is experiencing a shift from SPECT to PET as a         result of molly shortages combined with changes in reimbursement.        Positron is in an ideal position to capitalize on this shift more  so        than any other imaging company. The Attrius™ is a state of the  art,        Frost & Sullivan New Product Innovation Award winning, device  that was        designed to be optimized for Cardiac imaging allowing physicians  an easy        transition to PET. Our pipeline for PET systems has had  significant        increases each month since we launched the Attrius™ late last  year. Our        current pipeline has over 55 potential and/or pending sales with  the        second half on the year still too follow. We have done a very good  job        of positioning Positron to meet this new demand. Based on the  current        interest we believe we will meet or exceed our projected system  sales        moving forward. Positron’s objective is to be the leader in  cardiac PET        solutions. We believe we will continue to see substantial growth  from        both devices and radiopharmaceuticals."

About Positron: Positron  founded in 1983, is a molecular imaging        company focused on Nuclear Cardiology. Positron utilizes its  proprietary        product line to provide unique solutions to the Nuclear Medicine        community ranging from imaging systems to radiopharmaceutical        distribution. Positron products include: the Attrius™, a PET  imaging        device; the Pulse®, a SPECT imaging device; the Nuclear  Pharm-Assist®,        an automated radiopharmaceutical distribution device; and the        Tech-Assist™, a radiopharmaceutical injection shield. Positron is        headquartered in Indianapolis, Indiana. More information about  Positron        is available at www.positron.com.

 

730 Postings, 5073 Tage OttomanRosendahlNEWS Update

 
  
    #38
1
21.05.10 18:04
VPRESS RELEASE issued at 11:20am on 5/21/10.

1. Positron has seen 55 confirmed/possible orders for the PET Scanner (55 X ca. 3,5 Mio.$) in the 1st FOUR months of 2010 alone.

2. Their PET Scanner inquiries are increasing TEN-FOLD.

3. They expect even more interest than anticipated in 2010.

4. The Covidien partnership with the apparent radio-pharm units has been inked and is not even factored into these estimates.

5. Once the Covidien partnership and pipeline of products is PUBLICLY announced...the share price will skyrocket.


Was für ein Potenzial ; )  

4951 Postings, 4447 Tage 0815axQuarterly Report

 
  
    #39
21.05.10 20:47
The numbers of shares outstanding of each of the issuer's classes of common equity, as of May 20, 2010, are as follows: 594,719,778


Date : 05/20/2010 @ 5:05PM
Source : Edgar (US Regulatory)
Stock : (POSC)

http://ih.advfn.com/...=nmona&article=42917128&symbol=NB^POSC
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axPositron Sees Tenfold Increase in Quote Proposals

 
  
    #40
24.05.10 10:43

Positron  Sees Tenfold Increase in Quote Proposals      
Written by Staff and Wire Reports   
Saturday, 22 May 2010 11:22
 

Shares  of Positron Corporation (OTCBB:POSC),  the molecular imaging solutions company  focused on Nuclear Cardiology, rose nearly 16% after they stated that over the  first 4 months of 2010 that it has seen tremendous interest in their Attrius™  dedicated cardiac PET scanner. The Attrius™ was introduced in the  4th quarter of 2009 and has been met with critical acclaim  throughout the molecular imaging industry.

Patrick G. Rooney, Positron Corporation’s CEO states, “The Nuclear Cardiology  industry is experiencing a shift from SPECT to PET as a result of molly  shortages combined with changes in reimbursement. Positron is in an ideal  position to capitalize on this shift more so than any other imaging company. The  Attrius™ is a state of the art, Frost & Sullivan New Product Innovation  Award winning, device that was designed to be optimized for Cardiac imaging  allowing physicians an easy transition to PET. Our pipeline for PET systems has  had significant increases each month since we launched the Attrius™ late last  year.

Our current pipeline has over 55 potential and/or pending sales with the  second half on the year still too follow. We have done a very good job of  positioning Positron to meet this new demand. Based on the current interest we  believe we will meet or exceed our projected system sales moving forward.  Positron’s objective is to be the leader in cardiac PET solutions. We believe we  will continue to see substantial growth from both devices and  radiopharmaceuticals."

 
Positron Corp
    0.13  +0.02 (+15.32%)

 

*amM - keine Kaufempfehlung
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axPOSC Exhibits at the Society of Nuclear Medicine M

 
  
    #41
01.06.10 17:51
01.06.2010 17:48
http://www.finanznachrichten.de/...diac-optimized-pet-scanner-004.htm

Positron Exhibits at the Society of Nuclear Medicine Meeting to Promote Their Cardiac Optimized PET Scanner

Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, will exhibit at the upcoming Society of Nuclear Medicine Meeting (SNM) in Salt Lake City, UT June 5th-9th to promote their cardiac optimized PET scanner, the Attrius™ (www.snm.org).

The SNM Annual Meeting has been recognized by thousands of professional attendees as the premier event for educational and networking opportunities in molecular imaging and nuclear medicine. Positron will utilize the SNM annual conference as a platform to educate its attendees about the benefits of cardiac PET and promote the Attrius™.

With the continued uncertainty of the worlds Molybdenum supply and recent increase in PET reimbursement&decrease in SPECT reimbursement, cardiac PET has seen a significant rise in demand as doctors and hospitals look toward modalities that offer better medicine to their patients while decreasing operational costs. Joseph Oliverio, Chief Technology Officer states, "The demand for Cardiovascular PET imaging is rapidly increasing as it enables the physician to provide better patient care through a more accurate diagnosis, the potential to reduce unnecessary downstream procedures and limit radiation exposure." Mr. Oliverio also went on to state, "The Attrius™ has a small footprint, robust standard cardiovascular software package, competitive scan times and an affordable cost of entry making the Attrius™ the right choice for enhancing the capabilities of a Cardiovascular practices."

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at (317)576-0183.

Contacts:

Positron Corporation
Joseph Oliverio, (317) 576-0183



© 2010 Business Wire
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axPositron Key Points & Developments

 
  
    #42
17.06.10 19:20
17.06.2010 18:59
http://www.finanznachrichten.de/...on-key-points-developments-004.htm

Positron Key Points & Developments

Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology states the Company's key points and developments.

Positron's core focus is to leverage their unique technologies and competencies to offer an industry unique total customer solution which includes low cost molecular imaging devices and service, disease specific software, radiopharmaceutical distribution delivery systems, and imaging agents for Nuclear Cardiology. Positron's strategy is to utilize all of its innovative equipment to maximize market share within the molecular imaging market.

Positron operates through two segments: Molecular Imaging Devices and Radiopharmaceutical Products.

(...weiter siehe LINK)
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axImagin Molecular Corporation Acquires ...

 
  
    #43
17.06.10 19:37
17.06.2010 19:31
http://www.finanznachrichten.de/...alued-at-dollar-35-million-004.htm

Imagin Molecular Corporation Acquires an Investment Position in Positron Corporation Currently Valued at $35 Million

The Shareholders of Imagin Molecular Corporation ("IMGM") have approved, through a consent of over 51% of shareholder vote, certain transactions wherein IMGM completed the acquisition of 3,100,000 Class B Preferred Shares of Positron Corporation which shares are convertible on a 1 for 100 basis into Positron common shares. This position marked to the current market price for Positron Corporation common shares has a value of in excess of $35 million. It is IMGM's intention to hold the Positron Class B Preferred shares for investment purposes. The consideration for the exchange of the Positron investment position is the issuance of 310,000,000 common shares of IMGM to IMAGIN Diagnostic Centres, Inc. (IDC) a private Canadian company that is in the PET scanning business in Canada and a historical owner of the 3,100,000 Class B preferred block equity position. IMGM simultaneously announces its intent to build Cardiac Disease Reversal and Prevention Clinics across Canada and, after initial success, across the USA and globally. The new subsidiary will be named "Positron Cardiac CARE Clinics". These clinics will base its imaging technology on Positron's Attrius™ dedicated cardiac PET scanners.

Currently IMGM holds approximately one Positron common share equivalent for each IMGM common share outstanding. Positron preferred shares have been held by IMGM since 2005. Upon completion of the exchange of Positron preferred shares for IMGM common shares, IMGM will own the equivalent of 386,235,800 Positron common shares and upon completion of this transaction IMGM will have 405,000,000 common shares outstanding with no significant debt or preferred stock outstanding.

(...weiter siehe LINK)
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axPositron seeing substantial accumulation...

 
  
    #44
20.06.10 13:29

http://biomedreports.com/articles/most-popular/44674-positron-seeing-substantial-accumulation-may-pierce-resistance-levels.html

 

Positron seeing substantial accumulation. May pierce resistance  levels.      
     
Written by M.E.Garza   
Thursday, 17 June 2010 14:32
 

Positron  Corporation (OTCBB:POSC), a leader in molecular imaging and solutions  specializing in the field of Nuclear Cardiology has just released a  report over the news wires highlighting some of the company's key points  and developments.

   

The stock has been seeing quite a bit of accumulation since shares  broke the $.10 support level a few days ago and Thursday, shares closed  up 11.6% at $.125. We believe the stock will climb higher pending  announcements and long awaited official revelation of a key relationship  or two with big-cap firms in the biotech imaging space. Those  relationships and developments, as they are announced, may signal what  investors have been waiting for: the validation and start of next level  of commercialization and deployment activities surrounding the company's  Molecular Imaging Devices and Radiopharmaceutical Products.

Here is a marked up technical analysis chart of the company:

(...weiter siehe LINK)

 

-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axPositron Announces Sales of Attrius PET Scanners

 
  
    #45
21.06.10 18:52
http://www.finanznachrichten.de/...es-of-attrius-pet-scanners-004.htm

21.06.2010 15:44
Positron Announces Sales of Attrius™ PET Scanners

Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, announces the sales of four Attrius™ PET scanners to prominent cardiology practices and orders six Attrius™ PET scanners from its joint venture, Neusoft Positron Medical Systems for immediate delivery.

As a result of the Centers for Medicare&Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule whereby reimbursement for cardiac PET increased and reimbursement for SPECT decreased there has been a significant increase in demand for cardiac PET imaging. When combining the economic and medical imaging advantages of cardiac PET compounded with the continued shortage of Molybdenum, the parent radioisotope used in SPECT imaging, this increase in the demand for cardiac PET is a trend that is expected to continue.

Positron's cardiac optimized dedicated PET scanner the Attrius™ is the right choice at the right time for cardiovascular practices. With recent sales, Positron has met its six month projections and predicts greater demand moving forward. Based on Positron's sales pipeline and in preparation of meeting the next six month projections, the Company has place a purchase order for six systems for their earliest delivery. Positron's organic growth targets sales of 17 PET systems for 2010, 50 PET systems for 2011 and 125 PET systems for 2012 and fully expects to meet these goals.

Patrick G. Rooney, Chief Executive Officer of Positron stated, "Positron has always been a leader in cardiac PET and we continue to make progress that further validates our position that PET is the future of nuclear cardiology. Positron is ideally positioned with the Attrius™ as the only dedicated cardiac PET offering available. This year has seen the emergence of cardiac PET and Positron. Our objective is to meet the strong demand and be the full solutions provider for cardiac PET adopters. Positron projects an increase in sales every quarter for the foreseeable future and is prepared to deliver. Positron's corporate focus is aggressive growth while staying on track to deliver positive earnings within 18 months."

(...weiter siehe LINK)
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axPositron is Increasing Production of Attrius ...

 
  
    #46
09.07.10 15:55
http://www.finanznachrichten.de/...on-of-attrius-pet-scanners-004.htm

08.07.2010 18:31
Due to Demand Positron is Increasing Production of Attrius™ PET Scanners

Positron Corporation (OTCBB:POSC), a molecular imaging and solutions company specializing in Nuclear Cardiology and a leader in Cardiac PET, announces that due to a greater demand for the Attrius™ PET scanner, the Company has recently begun increasing production capacities with its joint venture, Neusoft Positron Medical Systems.

Positron's award-winning, cardiac optimized PET scanner, the Attrius™, is the only advanced, dedicated, cost-effective PET scanner in the marketplace. The introduction of the Attrius™ last year has generated excitement throughout the cardiac molecular imaging industry. Facilitated by the increase in reimbursement for cardiac PET and an industry-wide movement to better and more efficient medical imaging, Positron's Attrius™ has seen unprecedented interest and sales. As a result of the recent sales, Positron has met its six month projections and has to increase production earlier than previous estimations. Based on Positron's current sales and a more robust pipeline, the Company believes that they will surpass 2010 and 2011 targets of approximately 70 systems in the next 18 months.

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at (317)576-0183.

Contacts:

Positron Corporation
Patrick G. Rooney, (317)576-0183



© 2010 Business Wire
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axOpening of cGMP Manufacturing Facility

 
  
    #47
10.08.10 16:09
10.08.2010 15:37
http://www.finanznachrichten.de/...gmp-manufacturing-facility-004.htm

Positron Announces Opening of cGMP Manufacturing Facility
Facility to Focus on Production of Positron Emission Tomography Pharmaceuticals

Positron Corporation (OTCBB:POSC), a molecular imaging and solutions company specializing in Nuclear Cardiology and a leader in Cardiac PET, announced today the opening of a cGMP ready (current good manufacturing practices) facility in Indiana for the manufacturing of both radioactive and non-radioactive pharmaceutical products and devices.

"The opening of this facility marks a significant milestone in Positron's expansion into the consumables market that began with the acquisition of Dose Shield in 2008," stated John Zehner, COO of Positron. "Radioactive and non-radioactive pharmaceutical products are a key component of our Company's growth strategy; the opening of such a facility affords us significant advantages in every aspect of our business, which enables us to remain competitive in the future. The opening of this manufacturing facility was critical to our plan, as we are now equipped with the staff, equipment and space necessary to manufacture a variety of radioactive and non-radioactive pharmaceutical products. While the Company's plan is to focus on small batch, radioactive PET products, the facility will also be utilized to support current and future Positron equipment, as well as, expand into new markets. We are presently in discussions with several entities that can utilize our contract manufacturing services," concluded Mr. Zehner.

The Company noted the approximate 10,000 square foot facility, with room for expansion, contains ample clean room space and laboratory equipment to support the production of pharmaceutical and support products for both industrial and medical use. These products will meet or exceed Food and Drug Administration (FDA) current good manufacturing practices (cGMP's). This will allow for the production of products under 510k's, ANDA's, NDA's and IND's, as well as, certified compounding products for pharmacy use.

...(weiter siehe LINK)

© 2010 Business Wire
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axStrategic Alliance with Covidien

 
  
    #48
19.08.10 15:31
19.08.2010 15:10
http://www.finanznachrichten.de/...ovative-distribution-model-004.htm

Positron Announces Strategic Alliance with Covidien; to Develop Innovative Distribution Model

Positron Corporation (OTCBB:POSC), announced it has signed an agreement with Covidien (NYSE:COV), a leading global provider of healthcare products, under which Covidien will provide technical assistance to Positron in connection with Positron's development of technology to automate the compounding of radiopharmaceuticals.

The agreement combines Covidien's expertise in radiopharmaceuticals and regulatory issues with Positron's expertise in automation and radiopharmaceuticals. Automating the distribution of radiopharmaceuticals has many benefits, ranging from worker safety to cost savings to enhanced customer service.

"Positron continues to provide unique solutions to the molecular imaging community," said John Zehner, COO of Positron. "This agreement provides Positron with various advantages and additional resources. We are very excited to collaborate with Covidien on this project."

... (weiter siehe LINK)
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axQuarterly Report (10-Q)

 
  
    #49
24.08.10 06:44

For the quarterly period ended
 
JUNE 30, 2010

 

LINK: ih.advfn.com/p.php

 

The numbers of shares outstanding of each  of the issuer's classes of common equity, as of August 23, 2010, are as  follows: 773,452,547

Common Stock: $0.01 par value;  800,000,000 shares authorized

---

Customer deposits represent amounts paid to  the Company by customers for devices in advance of manufacturing  completion and/or shipment of the device to the customer. Deposit  amounts may vary depending on the contract. Included in customer  deposits at June 30, 2010 were deposits of approximately $669,000 from a  customer that had placed an order for five Nuclear Pharm-Assist™  systems. As of the date of this report, there can be no assurance that  this customer will fulfill its order for these devices. Accordingly,  deposits related to this customer have been reclassified from unearned  revenue to customer deposits. Also included in customer deposits at June  30, 2010, are $390,000 of deposits for sales of two Attrius™ Cardiac  PET systems.  At June 30, 2010, the Company paid $1,149,000 in  deposits for six Attrius machines for which the Company has six  pending sales contracts as of August 23, 2010.

--

Business Transaction
 
 
On  August 18, 2010, the Company announced a strategic alliance with  Covidien a large global healthcare company for product development of  its proprietary dose dispensing devise.  The Company will act as an  independent contractor to design and develop a new version of its  proprietary automated dose dispensing equipment specifically designed  for use exclusively with Covidien radiopharmaceutical products.

--

Cash and cash  equivalents at June 30, 2010 were $3,411,000 compared to $165,000 at  December 31, 2009. The increase in cash is due in large part to  significant equity investments made during the six months ended June 30,  2010 and deposits received for Attrius systems not yet shipped.

 

(Quelle: ihub / investorshub.advfn.com/boards/board.aspx )

 

 

*amM - keine Kaufempfehlung
-----------
*amM - keine Kaufempfehlung

4951 Postings, 4447 Tage 0815axPositron Opens State-of-the-Art Training Center

 
  
    #50
13.09.10 17:32
http://ih.advfn.com/...pid=nmona&article=44340308&symbol=POSC

Date : 09/13/2010 @ 7:30AM
Source : GlobeNewswire Inc.
Stock : Positron Corporation (POSC)

Positron Corporation (OTCBB:POSC), a molecular imaging company specializing in Nuclear Cardiology and a leader in Cardiac PET, announced today the grand opening of its Clinical and Technical Cardiovascular PET Training Institute in Niagara Falls, NY.

The training center will educate physicians, technologists, nurses and administrators on the use and benefits of cardiac PET imaging in the daily operations of their facility.  The training will be done in a partnership with the Heart Center of Niagara where Positron's medical director, Michael E. Merhige, M.D., F.A.C.C currently operates a Coronary Artery Disease Reversal and Prevention Center guided by Positron PET imaging technologies.

Positron's chief technical officer, Joe Oliverio, stated, "This center will be a critical tool in building awareness of the tangible benefits a dedicated cardiac PET scanner yields.  Creating a center specifically geared towards disseminating information is critically important as we work to grow the adaptation of PET scanners into the medical imaging marketplace.  As an early adaptor of cardiac PET imaging, Dr. Merhige is an ideal ambassador to the medical community; tapping into the combined decades of experience Dr. Merhige and Positron's clinical staff possess, will allow a seamless transition of users from SPECT to PET."

Dr. Michael E. Merhige said, "Cardiac PET has been around since 1995, but only until very recently has the necessary peer-reviewed literature been available to allow for its proper recognition.  PET scanning for cardiac use exposes the patient to significantly reduced levels of radiation, compared to SPECT, while affording physicians a highly effective diagnostic tool.  I am pleased to play a role in educating my peers on the benefits of a cardiac PET scanner."  

4951 Postings, 4447 Tage 0815axPOSC Announces Sales of Attrius(TM) PET Scanners

 
  
    #51
13.09.10 19:20
Positron Announces Sales of Attrius(TM) PET Scanners; Reaffirms Growth Targets

Wednesday September 8, 2010, 8:30 am EDT
http://finance.yahoo.com/news/...s-of-pz-2378364232.html?x=0&.v=1

INDIANAPOLIS, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC - News), a leading molecular imaging company specializing in the field of nuclear cardiology, announced today it has placed orders on its sales of three Attrius(TM) PET scanners. The sales of these systems are for leading cardiology practices and hospitals. The Company also reaffirmed its growth targets as previously disclosed, and is anticipating steady growth acceleration through 2012.

"The outlook for 2010 and beyond is very promising - with our leading market position and steady increase of new orders, the next few years should be an exciting period for Positron. Cardiac PET is the future of nuclear cardiology and we believe the investments made in equipment and infrastructure should allow us to meet the growing interest in PET. Our overriding objective is to meet the strong demand and be the provider of choice for cardiac PET adopters," said Patrick G. Rooney, chief executive officer of Positron. "While we're extremely focused on excelling in this rapidly growing field, we're also very focused on expanding our pharmaceutical business. This enables us to combine our unique products in innovative ways that provides the full package to the cardiology industry. All of our actions have one common goal in mind of increasing the bottom line that will deliver value to our shareholders."

Positron has received additional orders during the third quarter of 2010 and anticipates the fourth quarter will be its strongest yet. With the current run rate, the Company fully anticipates by the end of 2010 it will reach its sales goal of approximately 12 to 15 Attrius(TM) PET systems which equates to approximately $10 million to $12 million in sales, part of which will be recognized in the first quarter of 2011. The Company also expects to begin generating revenue from its radiopharmaceutical distribution and manufacturing businesses, which should come on line at the beginning of the fourth quarter.

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

Contact:

Positron Corporation
Patrick G. Rooney
(317) 576-0183  

4951 Postings, 4447 Tage 0815axASNC 2010 (September 25th)

 
  
    #52
13.09.10 19:28
ASNC 2010 - CARDIAC PET SYMPOSIUM

Sponsored by Positron
http://www.positron.com/

Featuring K. Lance Gould, M.D.
Saturday, September 25th at 7:00pm
The Independence Ballroom Downtown Marriott

http://us1.campaign-archive.com/...amp;id=8def15621c&e=c54aec95bb  

4951 Postings, 4447 Tage 0815axRodman & Renshaw Annual Global Investment Conferen

 
  
    #53
13.09.10 19:31
Rodman & Renshaw Annual Global Investment Conference

2010-09-14
11:40 AM Positron Corporation (OTC BB: POSC)

http://www.meetmax.com/sched/event_6089/~public/h/...ml?event_id=6089  

4951 Postings, 4447 Tage 0815axPOSC Power Point Presentation

 
  
    #54
15.09.10 10:33
Click the link below to download the presentation from the Rodman & Renshaw Annual
Global Investment Conference held on September 14, 2010

http://www.synergyfinancial-llc.com/files/...Point_R_R_Conference.ppt  

4951 Postings, 4447 Tage 0815axTrade Show Schedule 2010

 
  
    #55
15.09.10 11:42
http://positron.com/trade_show_schedule.html

Positron Corporation
7715 Loma Ct., Suite A
Fishers, IN 46038

Toll Free: 866.613.7587
Phone: 317.576.0183
Fax: 317.576.0358

sales@positron.com  

Seite: < 1 | 2 | 3 >  
   Antwort einfügen - nach oben